Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Janssen_COVID-19_Vaccine
|
| gptkbp:clinicalTrials |
over 40,000
multiple countries Phase 3 |
| gptkbp:community |
significant in pandemic response
|
| gptkbp:communityOutreach |
engages local communities
|
| gptkbp:communityPartnerships |
collaborates with NGOs
|
| gptkbp:contraindication |
thrombosis with thrombocytopenia syndrome
|
| gptkbp:developedBy |
gptkb:Johnson_&_Johnson
|
| gptkbp:dimensions |
contributes to herd immunity
|
| gptkbp:diseaseResistance |
intramuscular injection
logistical issues adheres to ethical standards aim to educate the public published in medical journals focus on underserved populations aim to increase public trust committed to sharing data ongoing evaluations conducted. part of pandemic response strategy |
| gptkbp:distribution |
global
|
| gptkbp:drugInterdiction |
1
|
| gptkbp:emergencyServices |
granted in February 2021
|
| gptkbp:endOfProduction |
under investigation
|
| gptkbp:evaluates |
approximately 66% effective against moderate to severe COVID-19
|
| gptkbp:firstAwarded |
over 20 million in the U.S.
|
| gptkbp:foughtAgainst |
varies by variant
|
| gptkbp:historicalResearch |
with various health organizations
|
| gptkbp:hostsEvents |
important for safety assessments
|
| https://www.w3.org/2000/01/rdf-schema#label |
Johnson & Johnson vaccine
|
| gptkbp:incubationPeriod |
involves multiple regulatory agencies
|
| gptkbp:isIncorporatedIn |
reduces transmission risk
|
| gptkbp:launchDate |
rapid due to pandemic urgency
|
| gptkbp:marketSegment |
conducted_by_CDC
|
| gptkbp:missileSystem |
gptkb:VAERS
|
| gptkbp:muzzleVelocity |
strategies in place for misinformation
|
| gptkbp:notable_event |
required for administration
|
| gptkbp:notable_player |
stable at refrigerator temperatures
single-dose vaccine history of severe allergic reactions involves local leaders mixed due to side effects repurposed adenovirus supported_by_U.S._government |
| gptkbp:produces |
gptkb:United_States
|
| gptkbp:providesAccessTo |
efforts to ensure equitable access
|
| gptkbp:providesGuidelinesFor |
updated as new data emerges
follow_CDC_recommendations |
| gptkbp:providesSupportFor |
with various countries
|
| gptkbp:raisesAwarenessAbout |
recommended for certain populations
|
| gptkbp:regulatoryCompliance |
follows strict guidelines
|
| gptkbp:researchContribution |
part_of_COVAX_initiative
|
| gptkbp:safetyFeatures |
ongoing
|
| gptkbp:searchAndRescueMissions |
peer-reviewed studies available
|
| gptkbp:sideEffect |
mild to moderate
|
| gptkbp:storage |
2 to 8 degrees Celsius
|
| gptkbp:survivability |
adults 18 years and older
|
| gptkbp:targets |
gptkb:COVID-19
|
| gptkbp:type |
viral vector vaccine
|
| gptkbp:volunteers |
consulted for recommendations
|
| gptkbp:wasAffecting |
protection wanes over time
|